Simcyp Limited Acquired by Certara
News Mar 07, 2012
Simcyp will operate as a business unit within Certara maintaining its Consortium business model and its focus on population-based PBPK/PD modelling and simulation services and software which it provides to the industrial pharmaceutical community.
The acquisition will significantly strengthen Simcyp’s ability to relate molecular structure to drug disposition through collaborative links with Tripos and extend Simcyp’s reach into clinical trial simulation, IVIVC and PK/PD modelling and simulation through collaborative links with Pharsight.
As a Certara company, Simcyp becomes an integral part of the Certara vision to provide a ‘joined-up’ drug-development information/modelling and simulation platform that will help drive-up efficiencies in R&D and drive-down operating costs within their global pharmaceutical industry clients.
In making the announcement, John Evans, Managing Director at Simcyp said: “We’re very pleased to become part of the Certara team. The acquisition by Certara will allow Simcyp to focus on its core competence whilst allowing us to draw on the broader drug development expertise available within the Certara family. Clients from across the spectrum of drug discovery and development will have access to a broader range of products and services, which will be enhanced by combining the attributes of Tripos, Simcyp, and Pharsight science and functionality.”
Certara’s President and Chief Executive Officer, Jim Hopkins, said: “We’re excited to add Simcyp to the Certara family, as a complement to Pharsight and Tripos. With the capabilities offered by Simcyp’s proprietary technology, combined with our existing software products and scientific consulting services, we expect to provide significant synergies to our mutual clients. From a translational science perspective, Simcyp’s preclinical simulation technologies, which include prediction of drug/drug interactions, fit perfectly between Certara’s existing discovery and clinical research offerings, thus enabling an end-to-end solution.”
The shareholders of Simcyp were advised by Livingstone Partners, the international mid-market corporate finance advisory firm with offices in London and Chicago, and by DLA Piper one of the UK’s leading law firms.
A new platform ensures that web services adhere to users’ preferences on how their data are stored and shared in the cloud. In a paper being presented at this week’s USENIX Networked Systems Design and Implementation conference, the researchers behind the platform, called Riverbed, show how it forces data center servers to only use data in ways that users explicitly approve.READ MORE
The days - or even weeks - spent waiting for the results of a cancer-screening test can feel like an eternity. Especially when early diagnosis and quick action are tied to better outcomes. Now, a new technique to analyze proteins expressed on cancer cells shows promise in more rapidly detecting these cell types.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019